NCT06304623View on ClinicalTrials.gov

SVF for Treating Pulmonary Fibrosis Post COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Pulmonary Fibrosis
Interventions
BIOLOGICAL

Autologous adipose-derived SVF IV administration

Subjects received an intravenous injection of autologous adipose-derived SVF.

Trial Locations (2)

21000

Hospital Escuela Oscar Danilo Rosales Arguello (HEODRA), León

61000

Hospital Escuela Cesar Amador Molina, Matagalpa

All Listed Sponsors
collaborator

Ministerio de Salud de Nicaragua

UNKNOWN

collaborator

Wake Forest University

OTHER

collaborator

National Autonomous University of Nicaragua

OTHER

lead

Michael H Carstens

OTHER

NCT06304623 - SVF for Treating Pulmonary Fibrosis Post COVID-19 | Biotech Hunter | Biotech Hunter